Emtricitabin a Tenofovir-alafenamid
Economic Operator with Whom the Contract Has Been Concluded
| Show detail | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1300/2022-SML | 19. 08. 2022 | Gilead Sciences s.r.o. | 12 805 562,00 | 11 641 420,00 | 12 805 562,00 | 11 641 420,00 | CZK |
Published Documents
| Show detail | |||||
|---|---|---|---|---|---|
| Písemná zpráva zadavatele_Emtricitabin a Tenofovir-alafenamid_EP.pdf | Písemná zpráva zadavatele | 29. 08. 2022 10:09 | Dokument není zavirovaný |
List of Participants
| Show detail | ||||||
|---|---|---|---|---|---|---|
| Gilead Sciences s.r.o. | Praha | 12 805 562,00 | 11 641 420,00 | CZK |
Price Actually Paid in Each Year of Performance
| 1300/2022-SML | 2023 | 3 457 110,82 | 3 142 827,97 |
| 1300/2022-SML | 2022 | 384 166,80 | 349 242,55 |